AGL 6.85 Increased By ▲ 0.05 (0.74%)
ANL 9.45 Increased By ▲ 0.05 (0.53%)
AVN 78.50 Increased By ▲ 0.38 (0.49%)
BOP 5.43 Increased By ▲ 0.03 (0.56%)
CNERGY 4.95 Increased By ▲ 0.10 (2.06%)
EFERT 77.85 Decreased By ▼ -0.15 (-0.19%)
EPCL 56.14 Increased By ▲ 0.34 (0.61%)
FCCL 15.35 Increased By ▲ 0.16 (1.05%)
FFL 6.44 Increased By ▲ 0.12 (1.9%)
FLYNG 8.13 Increased By ▲ 1.03 (14.51%)
GGGL 10.35 No Change ▼ 0.00 (0%)
GGL 16.54 Increased By ▲ 0.23 (1.41%)
GTECH 8.90 Increased By ▲ 0.72 (8.8%)
HUMNL 6.45 Increased By ▲ 0.06 (0.94%)
KEL 2.95 Increased By ▲ 0.03 (1.03%)
LOTCHEM 29.15 Increased By ▲ 0.20 (0.69%)
MLCF 27.89 Increased By ▲ 0.44 (1.6%)
OGDC 74.97 Decreased By ▼ -0.23 (-0.31%)
PAEL 16.16 Increased By ▲ 0.21 (1.32%)
PIBTL 5.57 Increased By ▲ 0.02 (0.36%)
PRL 17.07 Increased By ▲ 0.16 (0.95%)
SILK 1.09 Increased By ▲ 0.02 (1.87%)
TELE 10.72 Increased By ▲ 0.02 (0.19%)
TPL 8.06 Increased By ▲ 0.09 (1.13%)
TPLP 21.17 Increased By ▲ 0.34 (1.63%)
TREET 23.20 Increased By ▲ 0.20 (0.87%)
TRG 132.20 Increased By ▲ 3.50 (2.72%)
UNITY 23.50 Increased By ▲ 0.15 (0.64%)
WAVES 11.55 Increased By ▲ 0.01 (0.09%)
WTL 1.25 Increased By ▲ 0.14 (12.61%)
BR100 4,154 Increased By 41.3 (1%)
BR30 15,774 Increased By 179 (1.15%)
KSE100 41,503 Increased By 291.7 (0.71%)
KSE30 15,532 Increased By 122.2 (0.79%)
World

Moderna files for full US approval of COVID-19 vaccine

  • The development comes weeks after rival Pfizer Inc and its German partner BioNTech SE sought full approval for their COVID-19 vaccine in the United States.
  • Moderna said it will continue to submit data to the US Food and Drug Administration on a rolling basis over the coming weeks with a request for a priority review.
Published June 1, 2021
Follow us

Moderna Inc on Tuesday filed for full US approval of its COVID-19 vaccine, which is currently only authorized for emergency use in the country, becoming the second drugmaker to seek a broader regulatory nod.

The development comes weeks after rival Pfizer Inc and its German partner BioNTech SE sought full approval for their COVID-19 vaccine in the United States.

Full approval for the vaccines, which are at the forefront of global immunization efforts, could be an important step in allaying vaccine hesitancy, a growing concern in the United States and other wealthy nations.

It would also allow the vaccine makers to market their shots directly, as well as help companies and government agencies looking for vaccinations for their employees.

Moderna said it will continue to submit data to the US Food and Drug Administration on a rolling basis over the coming weeks with a request for a priority review.

On completion of the submission, the FDA will notify the company when it is formally accepted for review, it added.

Moderna has an agreement with the US government to supply 300 million doses of its COVID-19 vaccine.

More than 151 million doses of Moderna's vaccine have been distributed around the United States, with roughly 124.5 million shots administered as of Monday, according to the US Centers for Disease Control and Prevention.

Under an emergency use authorization, the FDA makes a product available to the public during an emergency based on the best available evidence, without waiting for all the evidence needed for full approval or clearance.

Moderna said in April its vaccine showed strong protection against the coronavirus six months after people received their second shot, with efficacy of more than 90% against all cases of COVID-19 and more than 95 percent against severe COVID-19.

Comments

Comments are closed.